It would be easy to view Merck & Co. Inc.'s recent decision to bail on two novel-target collaborations with Galapagos NV as a troubling sign that the industry is shying away from innovation and putting more investment dollars behind the safer, tried-and-true mechanisms of earlier blockbusters. (See BioWorld Today, Feb. 9, 2011.) Read More
